Hot Investor Mandate: Japan-Based PE Invests Early in Therapeutics, Devices and Diagnostics

18 Apr

A private equity firm headquartered in Tokyo, Japan with additional offices worldwide is currently making new investments from a 2016 fund. The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US, Israel and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm  is currently focused on private companies in the US, Israel and Japan. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: